{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T21:29:24Z","timestamp":1773696564815,"version":"3.50.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1038\/ncpgasthep0768","type":"journal-article","created":{"date-parts":[[2007,4,3]],"date-time":"2007-04-03T09:14:16Z","timestamp":1175591656000},"page":"202-214","source":"Crossref","is-referenced-by-count":38,"title":["Current therapy for autoimmune hepatitis"],"prefix":"10.1038","volume":"4","author":[{"given":"Aldo J","family":"Montano Loza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J","family":"Czaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpgasthep0768_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1053\/jhep.2002.34944","volume":"36","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ and Freese DK (2002) Diagnosis and treatment of autoimmune hepatitis. Hepatology 36: 479\u2013497","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR2","unstructured":"Montano-Loza AJ  et al.: Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int, in press"},{"key":"BFncpgasthep0768_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1089-3261(02)00029-6","volume":"6","author":"JM Vierling","year":"2002","unstructured":"Vierling JM and Flores PA (2002) Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 6: 825\u2013850","journal-title":"Clin Liver Dis"},{"key":"BFncpgasthep0768_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1055\/s-2002-35706","volume":"22","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ (2002) Treatment of autoimmune hepatitis. Semin Liver Dis 22: 365\u2013377","journal-title":"Semin Liver Dis"},{"key":"BFncpgasthep0768_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/hep.20732","volume":"42","author":"JJ Feld","year":"2005","unstructured":"Feld JJ  et al. (2005) Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 42: 53\u201362","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.1840180435","volume":"18","author":"PJ Johnson","year":"1993","unstructured":"Johnson PJ  et al. (1993) Meeting Report. International Autoimmune Hepatitis Group. Hepatology 18: 998\u20131005","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR7","unstructured":"Ichai P  et al.: Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl, in press"},{"key":"BFncpgasthep0768_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/jlts.2001.21449","volume":"4","author":"A Gonazalez-Koch","year":"2001","unstructured":"Gonazalez-Koch A  et al. (2001) Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 4: 302\u2013310","journal-title":"Liver Transpl"},{"key":"BFncpgasthep0768_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0140-6736(97)06478-7","volume":"353","author":"N Kerkar","year":"1998","unstructured":"Kerkar N  et al. (1998) De-novo autoimmune hepatitis after liver transplantation. Lancet 353: 409\u2013413","journal-title":"Lancet"},{"key":"BFncpgasthep0768_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.26756","volume":"34","author":"MA Heneghan","year":"2001","unstructured":"Heneghan MA  et al. (2001) Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 34: 464\u2013470","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00004836-200207000-00016","volume":"35","author":"J Kogan","year":"2002","unstructured":"Kogan J  et al. (2002) Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 35: 75\u201381","journal-title":"J Clin Gastroenterol"},{"key":"BFncpgasthep0768_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S0168-8278(00)00095-7","volume":"34","author":"S Kanzler","year":"2001","unstructured":"Kanzler S  et al. (2001) Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 34: 354\u2013355","journal-title":"J Hepatol"},{"key":"BFncpgasthep0768_CR13","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/j.1572-0241.2004.30457.x","volume":"99","author":"S Verma","year":"2004","unstructured":"Verma S  et al. (2004) Factors predicting relapse and poor outcome in type 1 autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 99: 1510\u20131516","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0768_CR14","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jhep.2005.06.006","volume":"43","author":"Y Miyake","year":"2005","unstructured":"Miyake Y  et al. (2005) Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 43: 951\u2013957","journal-title":"J Hepatol"},{"key":"BFncpgasthep0768_CR15","unstructured":"Montano-Loza A  et al.: Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol, in press"},{"key":"BFncpgasthep0768_CR16","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/j.1365-2036.2006.03113.x","volume":"24","author":"Y Miyake","year":"2006","unstructured":"Miyake Y  et al. (2006) Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 24: 1197\u20131205","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0768_CR17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1053\/gast.1996.v110.pm8608895","volume":"110","author":"SK Roberts","year":"1996","unstructured":"Roberts SK  et al. (1996) Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 110: 848\u2013857","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0768_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1365-2036.2006.03104.x","volume":"24","author":"A Floreani","year":"2006","unstructured":"Floreani A  et al. (2006) Type 1 autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol 24: 1051\u20131057","journal-title":"Aliment Pharmacol"},{"key":"BFncpgasthep0768_CR19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1053\/jhep.2002.32485","volume":"35","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ  et al. (2002) Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 35: 890\u2013897","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jhep.2004.01.009","volume":"40","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ and Carpenter HA (2004) Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 40: 644\u2013650","journal-title":"J Hepatol"},{"key":"BFncpgasthep0768_CR21","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1111\/j.1572-0241.2001.05272.x","volume":"96","author":"KN Lim","year":"2001","unstructured":"Lim KN  et al. (2001) Autoimmune hepatitis in African Americans: presenting features and responses to therapy. Am J Gastroenterol 96: 3390\u20133394","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0768_CR22","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1440-1746.1998.tb00674.x","volume":"13","author":"K Nakamura","year":"1998","unstructured":"Nakamura K  et al. (1998) Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 13: 490\u2013495","journal-title":"J Gastroenterol Hepatol"},{"key":"BFncpgasthep0768_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/gut.50.5.713","volume":"50","author":"T Zolfino","year":"2002","unstructured":"Zolfino T  et al. (2002) Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 50: 713\u2013717","journal-title":"Gut"},{"key":"BFncpgasthep0768_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/hep.510250308","volume":"25","author":"GV Gregorio","year":"1997","unstructured":"Gregorio GV  et al. (1997) Autoimmune hepatitis in childhood: a 20 year survey. Hepatology 25: 541\u2013547","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR25","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/hep.21074","volume":"43","author":"AJ Czaja","year":"2006","unstructured":"Czaja AJ and Carpenter HA (2006) Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 43: 532\u2013538","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR26","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/j.1572-0241.2001.03782.x","volume":"96","author":"C Schramm","year":"2001","unstructured":"Schramm C  et al. (2001) Autoimmune hepatitis in the elderly. Am J Gastroenterol 96: 1587\u20131591","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0768_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1365-2036.2005.02403.x","volume":"21","author":"C Verslype","year":"2005","unstructured":"Verslype C  et al. (2005) Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 21: 695\u2013699","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0768_CR28","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1365-2036.2005.02488.x","volume":"21","author":"A Granito","year":"2005","unstructured":"Granito A  et al. (2005) Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther 21: 1273\u20131277","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0768_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jhep.2006.04.007","volume":"45","author":"T Al-Chalabi","year":"2006","unstructured":"Al-Chalabi T  et al. (2006) Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral center. J Hepatol 45: 575\u2013583","journal-title":"J Hepatol"},{"key":"BFncpgasthep0768_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.hepres.2006.06.007","volume":"36","author":"T Miyake","year":"2006","unstructured":"Miyake T  et al. (2006) Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 36: 139\u2013142","journal-title":"Hepatol Res"},{"key":"BFncpgasthep0768_CR31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1034\/j.1600-0528.2002.017401.x","volume":"174","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ and Donaldson PT (2000) Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 174: 250\u2013259","journal-title":"Immunol Rev"},{"key":"BFncpgasthep0768_CR32","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1023\/A:1020166605016","volume":"47","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ  et al. (2002) Genetic bases of autoimmune hepatitis. Dig Dis Sci 47: 2139\u20132150","journal-title":"Dig Dis Sci"},{"key":"BFncpgasthep0768_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/hep.510250211","volume":"25","author":"AJ Czaja","year":"1997","unstructured":"Czaja AJ  et al. (1997) Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 25: 317\u2013323","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR34","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0016-5085(99)70458-0","volume":"117","author":"AJ Czaja","year":"1999","unstructured":"Czaja AJ  et al. (1999) Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 117: 645\u2013652","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0768_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/hep.510310110","volume":"31","author":"K Agarwal","year":"2000","unstructured":"Agarwal K  et al. (2000) CTLA-4 gene polymorphism and susceptibility to type 1 autoimmune hepatitis. Hepatology 31: 49\u201353","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1053\/jhep.2002.30084","volume":"35","author":"A Vogel","year":"2002","unstructured":"Vogel A  et al. (2002) Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 35: 126\u2013131","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR37","first-page":"1322","volume":"100","author":"A Hirade","year":"2005","unstructured":"Hirade A  et al. (2005) Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am J Gastroenterol 100: 1322\u20131329","journal-title":"Gastroenterol"},{"key":"BFncpgasthep0768_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.gene.6363918","volume":"4","author":"A Vogel","year":"2003","unstructured":"Vogel A  et al. (2003) 77 C\/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence of a genetic link. Genes Immun 4: 79\u201381","journal-title":"Genes Immun"},{"key":"BFncpgasthep0768_CR39","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1053\/gast.1997.v112.pm9178696","volume":"112","author":"MD Strettell","year":"1997","unstructured":"Strettell MD  et al. (1997) Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 112: 2028\u20132035","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0768_CR40","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1572-0241.1998.224_a.x","volume":"93","author":"AN McNair","year":"1998","unstructured":"McNair AN  et al. (1998) Autoimmune hepatitis overlapping with primary sclerosing cholangitis in 5 cases. Am J Gastroenterol 93: 777\u2013784","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0768_CR41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/hep.510280210","volume":"28","author":"AJ Czaja","year":"1998","unstructured":"Czaja AJ (1998) Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 28: 360\u2013365","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR42","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1089-3261(02)00028-4","volume":"6","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ (2002) Treatment strategies in autoimmune hepatitis. Clin Liver Dis 6: 799\u2013824","journal-title":"Clin Liver Dis"},{"key":"BFncpgasthep0768_CR43","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0168-8278(02)00214-3","volume":"37","author":"PG Langley","year":"2002","unstructured":"Langley PG  et al. (2002) Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 37: 441\u2013447","journal-title":"J Hepatol"},{"key":"BFncpgasthep0768_CR44","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s10620-006-9336-5","volume":"51","author":"AJ Czaja","year":"2006","unstructured":"Czaja AJ and Carpenter HA (2006) Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 51: 968\u2013975","journal-title":"Dig Dis Sci"},{"key":"BFncpgasthep0768_CR45","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2006.05.011","volume":"45","author":"MA Heneghan","year":"2006","unstructured":"Heneghan MA  et al. (2006) Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 45: 584\u2013591","journal-title":"J Hepatol"},{"key":"BFncpgasthep0768_CR46","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/hep.1840110621","volume":"11","author":"AJ Czaja","year":"1990","unstructured":"Czaja AJ (1990) Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 11: 1044\u20131049","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR47","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJM199510123331502","volume":"333","author":"PJ Johnson","year":"1995","unstructured":"Johnson PJ  et al. (1995) Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 333: 958\u2013963","journal-title":"N Engl J Med"},{"key":"BFncpgasthep0768_CR48","first-page":"17","volume-title":"Clinical Transplants 1998","author":"EC Seaberg","year":"1999","unstructured":"Seaberg EC  et al. (1999) Liver transplantation in the United States from 1987\u20131998: updated results from the Pitt-UNOS liver transplant registry. In Clinical Transplants 1998, 17\u201337 (Eds Cecka JM and Terasaki PI) Los Angeles: UCLA Tissue Typing Laboratories"},{"key":"BFncpgasthep0768_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0168-8278(99)80017-8","volume":"30","author":"V Ratziu","year":"1999","unstructured":"Ratziu V  et al. (1999) Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 30: 131\u2013141","journal-title":"J Hepatol"},{"key":"BFncpgasthep0768_CR50","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/lt.500040313","volume":"4","author":"M Hayashi","year":"1998","unstructured":"Hayashi M  et al. (1998) Allograft rejection after liver transplantation for autoimmune liver disease. Liver Transpl Surgery 4: 208\u2013214","journal-title":"Liver Transpl Surgery"},{"key":"BFncpgasthep0768_CR51","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/j.1600-6143.2005.00801.x","volume":"5","author":"N Kerkar","year":"2005","unstructured":"Kerkar N  et al. (2005) Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplantation 5: 1085\u20131089","journal-title":"Am J Transplantation"},{"key":"BFncpgasthep0768_CR52","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/0016-5085(88)90503-3","volume":"95","author":"AJ Czaja","year":"1988","unstructured":"Czaja AJ  et al. (1988) Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 95: 448\u2013453","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0768_CR53","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/j.1478-3231.2005.01121.x","volume":"25","author":"P Tan","year":"2005","unstructured":"Tan P  et al. (2005) Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. Liver Int 25: 728\u2013733","journal-title":"Liver Int"},{"key":"BFncpgasthep0768_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/jhep.2002.30991","volume":"35","author":"MA Heneghan","year":"2002","unstructured":"Heneghan MA and McFarlane IG (2002) Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35: 7\u201313","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0168-8278(99)80065-8","volume":"30","author":"F Alvarez","year":"1999","unstructured":"Alvarez F  et al. (1999) Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 30: 222\u2013227","journal-title":"J Hepatol"},{"key":"BFncpgasthep0768_CR56","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1023\/A:1010683817344","volume":"46","author":"R Malekzadeh","year":"2001","unstructured":"Malekzadeh R  et al. (2001) Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 46: 1321\u20131327","journal-title":"Dig Dis Sci"},{"key":"BFncpgasthep0768_CR57","first-page":"771","volume":"90","author":"DH Van Thiel","year":"1995","unstructured":"Van Thiel DH  et al. (1995) Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 90: 771\u2013776","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0768_CR58","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","volume":"38","author":"BA Aqel","year":"2004","unstructured":"Aqel BA  et al. (2004) Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 38: 805\u2013809","journal-title":"J Clin Gastroenterol"},{"key":"BFncpgasthep0768_CR59","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0168-8278(00)80271-8","volume":"33","author":"PD Richardson","year":"2000","unstructured":"Richardson PD  et al. (2000) Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J Hepatol 33: 371\u2013375","journal-title":"J Hepatol"},{"key":"BFncpgasthep0768_CR60","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1155\/2004\/504591","volume":"18","author":"SM Devlin","year":"2004","unstructured":"Devlin SM  et al. (2004) Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 18: 321\u2013326","journal-title":"Can J Gastroenterol"},{"key":"BFncpgasthep0768_CR61","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1478-3231.2005.01107.x","volume":"25","author":"N Chatur","year":"2005","unstructured":"Chatur N  et al. (2005) Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 25: 723\u2013727","journal-title":"Liver Int"},{"key":"BFncpgasthep0768_CR62","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/01.mcg.0000177260.72692.e8","volume":"39","author":"AJ Czaja","year":"2001","unstructured":"Czaja AJ and Carpenter HA (2001) Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 39: 819\u2013825","journal-title":"J Clin Gastroenterol"},{"key":"BFncpgasthep0768_CR63","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2036.1994.tb00334.x","volume":"8","author":"A Danielsson","year":"1994","unstructured":"Danielsson A and Prytz H (1994) Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 8: 585\u2013590","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0768_CR64","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/j.1478-3231.2005.01122.x","volume":"25","author":"J Wiegand","year":"2005","unstructured":"Wiegand J  et al. (2005) Budesonide in previously untreated autoimmune hepatitis. Liver Int 25: 927\u2013934","journal-title":"Liver Int"},{"key":"BFncpgasthep0768_CR65","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3748\/wjg.v12.i9.1362","volume":"12","author":"A Csepregi","year":"2006","unstructured":"Csepregi A  et al. (2006) Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 12: 1362\u20131366","journal-title":"World J Gastroenterol"},{"key":"BFncpgasthep0768_CR66","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1053\/gast.2000.0010000001","volume":"119","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ and Lindor KD (2000) Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 119: 1312\u20131316","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0768_CR67","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.3748\/wjg.v9.i12.2681","volume":"9","author":"A Geier","year":"2003","unstructured":"Geier A  et al. (2003) Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 9: 2681\u20132685","journal-title":"World J Gastroenterol"},{"key":"BFncpgasthep0768_CR68","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1053\/gast.1996.v110.pm8536867","volume":"110","author":"DS Pratt","year":"1996","unstructured":"Pratt DS  et al. (1996) The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 110: 271\u2013274","journal-title":"Gastroenterology"},{"key":"BFncpgasthep0768_CR69","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/00042737-200504000-00012","volume":"17","author":"NK de Boer","year":"2005","unstructured":"de Boer NK  et al. (2005) Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur J Gastroenterol 17: 457\u2013461","journal-title":"Eur J Gastroenterol"},{"key":"BFncpgasthep0768_CR70","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2036.2005.02581.x","volume":"22","author":"NK de Boer","year":"2005","unstructured":"de Boer NK  et al. (2005) On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment. Aliment Pharmacol Ther 22: 447\u2013451","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep0768_CR71","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1478-3231.2006.01262.x","volume":"26","author":"ES Santos","year":"2006","unstructured":"Santos ES  et al. (2006) Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of the literature. Liver Int 26: 625\u2013629","journal-title":"Liver Int"},{"key":"BFncpgasthep0768_CR72","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1136\/ard.2004.032821","volume":"64","author":"V Germano","year":"2005","unstructured":"Germano V  et al. (2005) Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 64: 1519\u20131520","journal-title":"Ann Rheum Dis"},{"key":"BFncpgasthep0768_CR73","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0198-8859(00)00126-9","volume":"61","author":"M Fridkis-Hareli","year":"2000","unstructured":"Fridkis-Hareli M  et al. (2000) Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses. Hum Immunol 61: 640\u2013650","journal-title":"Hum Immunol"},{"key":"BFncpgasthep0768_CR74","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1056\/NEJM199906033402202","volume":"340","author":"EC Guinan","year":"1999","unstructured":"Guinan EC  et al. (1999) Transplantation of anergic histoincompatible bone marrow allografts. N Eng J Med 340: 1704\u20131714","journal-title":"N Eng J Med"},{"key":"BFncpgasthep0768_CR75","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s000110050433","volume":"48","author":"RM Wardrop","year":"1999","unstructured":"Wardrop RM and Whitacre CC (1999) Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res 48: 106\u2013119","journal-title":"Inflamm Res"},{"key":"BFncpgasthep0768_CR76","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/hep.510270611","volume":"27","author":"AW Lohse","year":"1998","unstructured":"Lohse AW  et al. (1998) Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 27: 1536\u20131543","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR77","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1478-3231.2006.01339.x","volume":"26","author":"H Tilg","year":"2006","unstructured":"Tilg H  et al. (2006) How to modulate inflammatory cytokines in liver diseases. Liver Int 26: 1029\u20131039","journal-title":"Liver Int"},{"key":"BFncpgasthep0768_CR78","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1572-0241.2004.04034.x","volume":"99","author":"KV Menon","year":"2004","unstructured":"Menon KV  et al. (2004) A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 99: 255\u2013260","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep0768_CR79","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/hep.20206","volume":"39","author":"S Naveau","year":"2004","unstructured":"Naveau S  et al. (2004) A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39: 1390\u20131397","journal-title":"Hepatology"},{"key":"BFncpgasthep0768_CR80","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/978-94-011-4000-3_33","volume-title":"Immunology and Liver","author":"VK Touhy","year":"2000","unstructured":"Touhy VK and Mathisen PM (2000) Gene therapy for autoimmune diseases. In Immunology and Liver 376\u2013385 (Eds Manns MP, Paumgartner G and Leuschner U) Dordrecht: Kluwer Academic Publishers"}],"container-title":["Nature Clinical Practice Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0768","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0768.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep0768.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:05:33Z","timestamp":1684440333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpgasthep0768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["BFncpgasthep0768"],"URL":"https:\/\/doi.org\/10.1038\/ncpgasthep0768","relation":{},"ISSN":["1743-4378","1743-4386"],"issn-type":[{"value":"1743-4378","type":"print"},{"value":"1743-4386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}